North Health Ltd. raised $6 million in financing to bring its oncology products to the market including the Neutrocheck, a ...
Dewpoint Therapeutics Inc. and Mitsubishi Tanabe Pharma Corp. have entered a research collaboration worth up to $480 million ...
New research confirmed long-term efficacy and safety of a novel minimally invasive procedure with Insightec Inc.’s Exablate transcanial magnetic resonance-guided focused ultrasound system to alleviate ...
Biopharma companies have raised $97.42 billion through November 2024, up 46% from $66.79 billion during the same period in 2023 and also more than $56.56 billion in 2022. However, this year’s total ...
Beijing Hanmi Pharm. Co. Ltd. broke ground on a ₩140 billion (US$98.65 million) large-scale project to build a near-500,000-square-foot China base near Beijing Capital International Airport in efforts ...
Bring your dog to work day looks a little different at Spotitearly. The Tel Aviv-based company asks its canine workers to bring their whole selves to the job – particularly their finely trained noses ...
The European Commission approved Novo Holding A/S’ acquisition of Catalent Inc., a global contract development and manufacturing organization expected to help Novo Nordisk A/S keep up with increasing ...
Voyager Therapeutics Inc.’s recent selection of a lead development candidate, VY-1706, for its tau silencing gene therapy program in Alzheimer’s disease brought renewed attention to the target, which ...
Biopharma money raised to-date and by month in 2023, including public, private and other financings.
Total raised in public, private and other financings of biopharma companies, comparing 2019-2024.
Merus NV gained accelerated U.S. FDA approval of Bizengri (zenocutuzumab) as the first and only targeted therapy indicated for NRG1-positive pancreatic adenocarcinoma and non-small-cell lung cancer ...
Our immune cells are not just “defenders” against deadly viruses and pathogens but also a great balancer for tissue ...